- NorthStar Medical Radioisotopes will supply Ariceum Therapeutics with high-purity Actinium-225 (Ac-225) for developing targeted cancer therapies.
- Ariceum’s satoreotide will use Ac-225 to combat aggressive cancers like SCLC and pancreatic cancer.
NorthStar Medical Radioisotopes, LLC, a leader in radiopharmaceuticals, has signed a supply agreement with Ariceum Therapeutics, a biotech company specialising in radiopharmaceutical cancer treatments. The agreement ensures Ariceum receives non-carrier-added, high-purity Actinium-225 (Ac-225), a critical isotope for advancing its therapeutic pipeline.
The collaboration centres on Ariceum’s satoreotide (SS0110), a first-in-class antagonist targeting somatostatin receptor 2 (SSTR2). Designed as a theranostic agent, satoreotide combines diagnostic and treatment capabilities for cancers such as small cell lung cancer (SCLC), pancreatic cancer, and Merkel Cell Carcinoma. Early clinical trials have shown promising results.
Frank Scholz, CEO of NorthStar, emphasised the significance of addressing supply challenges for Ac-225: “We are proud to use our expertise to help innovative companies like Ariceum make new treatment therapies a reality for patients.”
Ariceum CEO Manfred Rüdiger highlighted the partnership’s importance in advancing clinical studies and future commercialisation: “NorthStar’s leadership in isotope production ensures a reliable supply of Ac-225 for our development programs.”
Overview of outsourcing trends 
